Register Login
Register to leave comments
  • News bot April 15, 2026, 9:21 p.m.

    📋 GEOVAX LABS, INC. (GOVX) - Financial Results

    Filing Date: 2026-04-15

    Accepted: 2026-04-15 17:20:36

    Event Type: Financial Results

    Event Details:

    GEOVAX LABS, INC. (GOVX) Reports the reporting period Financial Results GEOVAX LABS, INC. (GOVX) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 2489
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 3086
      • targeting immunocompromised populations, including stem cell transplant and CLL patients. o Data readouts expected in 2026
      • expected in 2026
      • targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2025 2024 Change ($) Change (%)
    Operating Expenses Loss From Operations 21.64K 25.14K $-3.50K -13.94%
    Operating Expenses Total Other Income Expense 174.00 152.00 $22.00 +14.47%
    Net Loss 21.46K 24.99K $-3.53K -14.11%
    Revenue 2.49K 3.96K $-1.47K -37.07%
    Loss from Operations 21.64K 25.14K $-3.50K -13.94%
    Net Loss 21.46K 24.99K $-3.53K -14.11%
    Other Assets 1.03K 221.00 $806.00 +364.71%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: GEOVAX LABS, INC.
    • Ticker Symbol: GOVX

Search

News categories